Background: Validus Pharmaceuticals LLC (“Validus”), headquartered in Parsippany, NJ, is a pharmaceutical holding company focused on the acquisition, reformulation, and commercialization of prescription products.
Cassel Salpeter:
Served as financial advisor to the company
Ran a broad, competitive sales process, identifying and contacting strategic and financial buyers both in the U.S. and internationally
Successfully identified a strategic acquirer looking to expand its presence in the U.S. markets through a platform acquisition
Challenges:
Navigating the regulatory hurdles of selling to an international buyer
Carving out certain products in the Validus portfolio for sales to other buyers
Ensuring a seamless technology transfer and transition of products with existing distribution agreements
Outcome: In February 2024, Validus was acquired by Rubicon Research (“Rubicon”). Rubicon is a specialty pharmaceutical company focused on the manufacturing of drugs across multiple dosage forms. The acquisition of Validus will expand their presence in the U.S. market for the manufacture and sale of prescription pharmaceuticals.
